Heartbeam Inc
heartbeam.comHeartBeam Inc (NASDAQ: BEAT) is a medical device company developing a wrist-worn cardiac monitoring device capable of generating a three-lead ECG outside of a clinical setting. The company has not yet commercialized its product and had no product revenue as of its 10-K filed March 12, 2026. HeartBeam is pre-revenue and competing in the ambulatory cardiac monitoring market, where existing technologies rely predominantly on single-lead ECG devices that cannot detect life-threatening conditions such as acute coronary syndrome or myocardial infarction. The company's product is designed to be removed from the wrist and held against the chest to capture three orthogonal cardiac leads, transmitting data via a third-party wireless carrier to healthcare providers, data centers, or ECG monitoring centers. Revenue, if realized, would depend on reimbursement from Medicare and commercial payers, who have historically classified mobile cardiac telemetry as experimental and investigational pending randomized clinical trial evidence.
Products & Services
Wrist-worn three-lead ECG cardiac monitoring device. The device detects three orthogonal cardiac leads and is designed to identify conditions including atrial fibrillation, acute coronary syndrome, and myocardial infarction. The platform includes AI-based personalized ECG monitoring with machine-learning algorithms (patent pending as of filing date) and a wearable buffering mechanism for onboard data pre-processing. Data transmission relies on a third-party wireless carrier network routed to healthcare providers or ECG monitoring centers.
Revenue Model
No product revenue reported as of the 10-K filed March 12, 2026. Anticipated revenue model is service-based cardiac monitoring fees, dependent on Medicare and commercial payer reimbursement for remote cardiac monitoring services.
Customers & Markets
End customers are cardiac patients and the prescribing physicians who order monitoring services. The addressable market is ambulatory cardiac monitoring outside of hospital settings, driven by the trend toward lower-cost, patient-friendly remote monitoring. Reimbursement gatekeepers are Medicare and commercial insurance payers.
Geographic Exposure
Incorporated in the United States. Patent filings span the US, South Korea, Australia, and Canada as of the 10-K filed March 12, 2026. No geographic revenue breakdown available given pre-revenue status.
Financial Snapshot
Loading...
